BridgeBio Oncology Therapeutics, Inc. Stock-Based Compensation
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Stock-Based Compensation of $11.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $7.23M, a 19975.00% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.87M, a 517.38% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.95M, a 401.87% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.43M, a 1741.09% increase year-over-year.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $11.10M 10-Q · filed 2026-08-11 | $14.04M derived: sum of 3 quarters · filed 2026-08-11 | $15.47M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $3.87M 10-Q · filed 2026-05-12 | $6.82M derived: sum of 2 quarters · filed 2026-05-12 | $8.24M derived: sum of 3 quarters · filed 2026-05-12 | $8.28M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2025-12-31 | $2.95M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $4.37M derived: sum of 2 quarters · filed 2026-04-30 | $4.41M derived: sum of 3 quarters · filed 2026-04-30 | $5.87M POS AM · filed 2026-04-30 | ||||
| 2025-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.46M derived: sum of 2 quarters · filed 2025-11-12 | $2.93M 10-Q · filed 2025-11-12 | $2.67M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2025-06-30 | $36.00K 10-Q · filed 2025-08-01 | $1.50M 10-Q · filed 2026-08-11 | $93.92K 10-Q · filed 2025-08-01 | $1.25M derived: sum of 3 quarters · filed 2026-05-12 | $1.33M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2025-03-31 | $627.00K 10-Q · filed 2026-05-12 | $57.92K 10-Q · filed 2025-05-15 | $1.21M derived: sum of 2 quarters · filed 2026-05-12 | $1.29M derived: sum of 3 quarters · filed 2026-05-12 | $1.37M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $587.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $664.40K derived: sum of 2 quarters · filed 2026-04-30 | $741.80K derived: sum of 3 quarters · filed 2026-04-30 | $4.42M POS AM · filed 2026-04-30 | $271.57K 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $77.40K 10-Q · filed 2024-11-14 | $154.80K derived: sum of 2 quarters · filed 2025-08-01 | $3.84M 10-Q · filed 2025-11-12 | $194.17K 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $77.40K 10-Q · filed 2025-08-01 | $116.77K 10-Q · filed 2025-08-01 | ||||||
| 2024-03-31 | $39.37K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |